Avandia Concerns Highlight Need To Change Diabetes Approval Standards

FDA should forgo use of glycemic control as a surrogate endpoint for clinical trials supporting the approval of type 2 diabetes therapies, Clifford Rosen said following the advisory committee review of GlaxoSmithKline's Avandia